<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504556</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-PRT018</org_study_id>
    <nct_id>NCT00504556</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation</brief_title>
  <official_title>A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety of a potential new drug DU-176b for the prevention of
      stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation
      (AF). The duration is 3 months of treatment and a 30 day follow-up visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjudicated Incidence of Bleeding Events</measure>
    <time_frame>3 months</time_frame>
    <description>Adjudicated Incidence of Bleeding Events during treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)</measure>
    <time_frame>3 months</time_frame>
    <description>liver enzyme (ALT and/or AST) and/or bilirubin (TBL) abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Cardiac Events MACE)</measure>
    <time_frame>3 months</time_frame>
    <description>MACE is defined as the composite of stroke [ischemic or hemorrhagic], Systemic embolic event (SEE), Myocardial Infarction (MI), Cardiovascular (CV) death, and hospitalization for any cardiac condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Biomarker D-dimer</measure>
    <time_frame>3 months</time_frame>
    <description>Mean (SD) change from baseline in D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Biomarker Prothrombin Fragments</measure>
    <time_frame>3 months</time_frame>
    <description>Mean (SD) change from baseline in Prothrombin Fragments 1 and 2 (F1 and F2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b</measure>
    <time_frame>3 months</time_frame>
    <description>Median (min, max) values of Cmin,ss; Cmax,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b</measure>
    <time_frame>3 months</time_frame>
    <description>Median (min, max) values of AUCss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b</measure>
    <time_frame>Day 28</time_frame>
    <description>Mean (SD) change from baseline in biomarker anti-Factor Xa [FXa] activity on Day 28, 1-3 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b</measure>
    <time_frame>Day 28</time_frame>
    <description>Mean (SD) change from baseline in biomarker endogenous FX activity on Day 28, 1-3 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b</measure>
    <time_frame>Day 28</time_frame>
    <description>Mean (SD) change from baseline in biomarker prothrombinase induced clotting time [PICT] on Day 28, 1-3 hours post dose.
PICT was determined by PICT aasay which is a plasma based functional assay to determine the anticoagulant activity on FXa and FIIa inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b</measure>
    <time_frame>Day 28</time_frame>
    <description>Mean (SD) change from baseline in biomarker prothrombin time (PT) on Day 28, 1-3 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b</measure>
    <time_frame>Day 28</time_frame>
    <description>Mean (SD) change from baseline in biomarker International Normalized Ratio (INR) on Day 28, 1-3 hours post dose.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1146</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b 30mg tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b 60mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b 30mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b 60mg tablets two times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>warfarin tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban (DU-176b)</intervention_name>
    <description>30mg tablet once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban (DU-176b)</intervention_name>
    <description>60mg tablet once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban (DU-176b)</intervention_name>
    <description>30mg tablet two times a day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban (DU-176b)</intervention_name>
    <description>60mg tablet two times a day</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>warfarin tablets</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 to 80 years old.

          2. Able to provide written informed consent.

          3. Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)

          4. A congestive heart failure, hypertension, age â‰¥ 75 years, diabetes, and prior stroke
             (CHADS2) index score of at least 2

        Exclusion Criteria:

          1. Subjects with mitral valve disease or previous valvular heart surgery

          2. Known contraindication to any anticoagulant including vitamin K antagonists such as
             warfarin

          3. Known or suspected hereditary or acquired bleeding or coagulation disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cadillac</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mostar</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuzla</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alberta</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antofagasta</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osorno</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventspils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaliningrad</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N.Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov on Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chernigov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chernivtsy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Former Serbia and Montenegro</country>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2015</results_first_posted>
  <disposition_first_submitted>August 25, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 25, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2010</disposition_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-coagulant</keyword>
  <keyword>Non-valvular</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Prevention of Blood Clots</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Non-valvular atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DU-176b 30mg qd</title>
          <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
        </group>
        <group group_id="P2">
          <title>DU-176b 30mg Bid</title>
          <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
        </group>
        <group group_id="P3">
          <title>DU-176b 60mg qd</title>
          <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
        </group>
        <group group_id="P4">
          <title>DU-176b 60mg Bid</title>
          <description>DU-176b 60mg tablets two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
        </group>
        <group group_id="P5">
          <title>Warfarin Tablets</title>
          <description>warfarin tablets
warfarin: warfarin tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="235"/>
                <participants group_id="P4" count="180"/>
                <participants group_id="P5" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="244"/>
                <participants group_id="P3" count="234"/>
                <participants group_id="P4" count="180"/>
                <participants group_id="P5" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="243"/>
                <participants group_id="P3" count="234"/>
                <participants group_id="P4" count="180"/>
                <participants group_id="P5" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacodynamic Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="236"/>
                <participants group_id="P3" count="228"/>
                <participants group_id="P4" count="170"/>
                <participants group_id="P5" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="204"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="128"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not meet entry criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>data monitor committee decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not in safety analysis set</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DU-176b 30mg qd</title>
          <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
        </group>
        <group group_id="B2">
          <title>DU-176b 30mg Bid</title>
          <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
        </group>
        <group group_id="B3">
          <title>DU-176b 60mg qd</title>
          <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
        </group>
        <group group_id="B4">
          <title>DU-176b 60mg Bid</title>
          <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
        </group>
        <group group_id="B5">
          <title>Warfarin Tablets</title>
          <description>warfarin tablets
warfarin: warfarin tablets</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="235"/>
            <count group_id="B2" value="244"/>
            <count group_id="B3" value="234"/>
            <count group_id="B4" value="180"/>
            <count group_id="B5" value="250"/>
            <count group_id="B6" value="1143"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="97"/>
                    <measurement group_id="B6" value="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="153"/>
                    <measurement group_id="B6" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="8.34"/>
                    <measurement group_id="B2" value="64.8" spread="8.83"/>
                    <measurement group_id="B3" value="64.9" spread="8.81"/>
                    <measurement group_id="B4" value="64.7" spread="8.96"/>
                    <measurement group_id="B5" value="66.0" spread="8.49"/>
                    <measurement group_id="B6" value="64.9" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="99"/>
                    <measurement group_id="B6" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="151"/>
                    <measurement group_id="B6" value="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="228"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="243"/>
                    <measurement group_id="B6" value="1116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="83"/>
                    <measurement group_id="B6" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="97"/>
                    <measurement group_id="B6" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moldova, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bosnia and Herzegovina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Adverse Cardiac Events MACE)</title>
        <description>MACE is defined as the composite of stroke [ischemic or hemorrhagic], Systemic embolic event (SEE), Myocardial Infarction (MI), Cardiovascular (CV) death, and hospitalization for any cardiac condition</description>
        <time_frame>3 months</time_frame>
        <population>safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
          <group group_id="O5">
            <title>Warfarin Tablets</title>
            <description>warfarin tablets
warfarin: warfarin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Adverse Cardiac Events MACE)</title>
          <description>MACE is defined as the composite of stroke [ischemic or hemorrhagic], Systemic embolic event (SEE), Myocardial Infarction (MI), Cardiovascular (CV) death, and hospitalization for any cardiac condition</description>
          <population>safety analysis set</population>
          <units>percent of subjects experiencing events</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="180"/>
                <count group_id="O5" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.5" upper_limit="4.3"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.9" upper_limit="5.3"/>
                    <measurement group_id="O3" value="4.3" lower_limit="2.1" upper_limit="7.7"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O5" value="2.4" lower_limit="0.9" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".4" lower_limit="0" upper_limit="2.3"/>
                    <measurement group_id="O2" value=".8" lower_limit=".1" upper_limit="2.9"/>
                    <measurement group_id="O3" value=".4" lower_limit="0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O5" value="1.6" lower_limit="0.4" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SEE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".4" lower_limit="0" upper_limit="2.3"/>
                    <measurement group_id="O2" value=".4" lower_limit="0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any stroke and/or SEE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".4" lower_limit="0" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.2" lower_limit=".3" upper_limit="3.6"/>
                    <measurement group_id="O3" value=".4" lower_limit="0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O5" value="1.6" lower_limit=".4" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9" lower_limit=".1" upper_limit="3.0"/>
                    <measurement group_id="O2" value=".4" lower_limit="0" upper_limit="2.3"/>
                    <measurement group_id="O3" value=".9" lower_limit=".1" upper_limit="3.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CV death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9" lower_limit=".1" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.6" lower_limit=".4" upper_limit="4.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2.0"/>
                    <measurement group_id="O5" value=".8" lower_limit=".1" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hospitalization for any cardiac condition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9" lower_limit=".1" upper_limit="3.0"/>
                    <measurement group_id="O2" value=".8" lower_limit=".1" upper_limit="2.9"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.2" upper_limit="6.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2.0"/>
                    <measurement group_id="O5" value=".4" lower_limit="0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Incidence of Bleeding Events</title>
        <description>Adjudicated Incidence of Bleeding Events during treatment period</description>
        <time_frame>3 months</time_frame>
        <population>safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
          <group group_id="O5">
            <title>Warfarin Tablets</title>
            <description>warfarin tablets
warfarin: warfarin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Incidence of Bleeding Events</title>
          <description>Adjudicated Incidence of Bleeding Events during treatment period</description>
          <population>safety analysis set</population>
          <units>percent of subjects with outcome event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="180"/>
                <count group_id="O5" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.0" upper_limit="9.3"/>
                    <measurement group_id="O2" value="12.7" lower_limit="8.8" upper_limit="17.5"/>
                    <measurement group_id="O3" value="7.3" lower_limit="4.3" upper_limit="11.4"/>
                    <measurement group_id="O4" value="18.3" lower_limit="13.0" upper_limit="24.8"/>
                    <measurement group_id="O5" value="8.0" lower_limit="5.0" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major or clinically relevant non-major bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.2" upper_limit="6.0"/>
                    <measurement group_id="O2" value="7.8" lower_limit="4.8" upper_limit="11.9"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.8" upper_limit="7.2"/>
                    <measurement group_id="O4" value="10.6" lower_limit="6.5" upper_limit="16.0"/>
                    <measurement group_id="O5" value="3.2" lower_limit="1.4" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.7" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="3.3" lower_limit="1.2" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.4" lower_limit="0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.367</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.104</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.864</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.002</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major or Clinically Relevant (CR) non-major bleeding</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major or Clinically Relevant (CR) non-major bleeding</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major or Clinically Relevant (CR) non-major bleeding</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.807</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major or Clinically Relevant (CR) non-major bleeding</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.119</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Major bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Biomarker D-dimer</title>
        <description>Mean (SD) change from baseline in D-dimer</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
          <group group_id="O5">
            <title>Warfarin Tablets</title>
            <description>warfarin tablets
warfarin: warfarin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Biomarker D-dimer</title>
          <description>Mean (SD) change from baseline in D-dimer</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="215"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-225" spread="809.3"/>
                    <measurement group_id="O2" value="-187.8" spread="776.8"/>
                    <measurement group_id="O3" value="-100.5" spread="461.6"/>
                    <measurement group_id="O4" value="-129.8" spread="771.4"/>
                    <measurement group_id="O5" value="-160.7" spread="635.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Biomarker Prothrombin Fragments</title>
        <description>Mean (SD) change from baseline in Prothrombin Fragments 1 and 2 (F1 and F2)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
          <group group_id="O5">
            <title>Warfarin Tablets</title>
            <description>warfarin tablets
warfarin: warfarin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Biomarker Prothrombin Fragments</title>
          <description>Mean (SD) change from baseline in Prothrombin Fragments 1 and 2 (F1 and F2)</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" spread="1312.0"/>
                    <measurement group_id="O2" value="-47.4" spread="1169.6"/>
                    <measurement group_id="O3" value="-51.4" spread="868.8"/>
                    <measurement group_id="O4" value="6.4" spread="1353.8"/>
                    <measurement group_id="O5" value="-74.6" spread="849.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b</title>
        <description>Median (min, max) values of Cmin,ss; Cmax,ss</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b</title>
          <description>Median (min, max) values of Cmin,ss; Cmax,ss</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmin,ss (ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="3.3" upper_limit="33.8"/>
                    <measurement group_id="O2" value="21.2" lower_limit="5.8" upper_limit="53.1"/>
                    <measurement group_id="O3" value="39.6" lower_limit="15.4" upper_limit="71.6"/>
                    <measurement group_id="O4" value="75.7" lower_limit="40.7" upper_limit="144.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss (ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="48.9" upper_limit="178.8"/>
                    <measurement group_id="O2" value="173.0" lower_limit="106.7" upper_limit="338.5"/>
                    <measurement group_id="O3" value="115.0" lower_limit="72.9" upper_limit="240.0"/>
                    <measurement group_id="O4" value="221.4" lower_limit="162.9" upper_limit="400.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)</title>
        <description>liver enzyme (ALT and/or AST) and/or bilirubin (TBL) abnormalities</description>
        <time_frame>3 months</time_frame>
        <population>safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
          <group group_id="O5">
            <title>Warfarin Tablets</title>
            <description>warfarin tablets
warfarin: warfarin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)</title>
          <description>liver enzyme (ALT and/or AST) and/or bilirubin (TBL) abnormalities</description>
          <population>safety analysis set</population>
          <units>percent subjects with liver related MA</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="180"/>
                <count group_id="O5" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, total &gt;= 3x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.3" upper_limit="3.8"/>
                    <measurement group_id="O2" value="0.9" lower_limit=".01" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.6" lower_limit="1.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="1.7" lower_limit="0.4" upper_limit="5.0"/>
                    <measurement group_id="O5" value="1.2" lower_limit="0.3" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, total &gt;= 3x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.1" upper_limit="3.1"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.1" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.3" upper_limit="3.8"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.1" upper_limit="4.1"/>
                    <measurement group_id="O5" value="0.8" lower_limit="0.1" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total bilirubin, total &gt;= 2x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.1" upper_limit="3.1"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.3" upper_limit="3.7"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="2.9" lower_limit="1.0" upper_limit="6.7"/>
                    <measurement group_id="O5" value="1.6" lower_limit="0.4" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT or AST &gt;=3 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.3" upper_limit="3.8"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.1" upper_limit="3.0"/>
                    <measurement group_id="O3" value="3.1" lower_limit="1.2" upper_limit="6.2"/>
                    <measurement group_id="O4" value="1.7" lower_limit="0.4" upper_limit="5.0"/>
                    <measurement group_id="O5" value="1.6" lower_limit="0.4" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT or AST &gt;=3 x ULN and TBL &gt;=2 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0" upper_limit="3.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b</title>
        <description>Median (min, max) values of AUCss</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b</title>
          <description>Median (min, max) values of AUCss</description>
          <units>ng*h/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="825" lower_limit="600" upper_limit="1862"/>
                    <measurement group_id="O2" value="1729" lower_limit="1176" upper_limit="3103"/>
                    <measurement group_id="O3" value="1728" lower_limit="1096" upper_limit="3125"/>
                    <measurement group_id="O4" value="3301" lower_limit="2485" upper_limit="5859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b</title>
        <description>Mean (SD) change from baseline in biomarker anti-Factor Xa [FXa] activity on Day 28, 1-3 hours post dose.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b</title>
          <description>Mean (SD) change from baseline in biomarker anti-Factor Xa [FXa] activity on Day 28, 1-3 hours post dose.</description>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="184"/>
                <count group_id="O4" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread=".96"/>
                    <measurement group_id="O2" value="1.91" spread=".97"/>
                    <measurement group_id="O3" value="2.42" spread="1.63"/>
                    <measurement group_id="O4" value="3.28" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b</title>
        <description>Mean (SD) change from baseline in biomarker endogenous FX activity on Day 28, 1-3 hours post dose.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b</title>
          <description>Mean (SD) change from baseline in biomarker endogenous FX activity on Day 28, 1-3 hours post dose.</description>
          <units>percent change of Endogenous FX activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="190"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.3" spread="26.4"/>
                    <measurement group_id="O2" value="-40.2" spread="25.5"/>
                    <measurement group_id="O3" value="-44.4" spread="25.7"/>
                    <measurement group_id="O4" value="-45.2" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b</title>
        <description>Mean (SD) change from baseline in biomarker prothrombinase induced clotting time [PICT] on Day 28, 1-3 hours post dose.
PICT was determined by PICT aasay which is a plasma based functional assay to determine the anticoagulant activity on FXa and FIIa inhibition.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b</title>
          <description>Mean (SD) change from baseline in biomarker prothrombinase induced clotting time [PICT] on Day 28, 1-3 hours post dose.
PICT was determined by PICT aasay which is a plasma based functional assay to determine the anticoagulant activity on FXa and FIIa inhibition.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="180"/>
                <count group_id="O4" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="5.2"/>
                    <measurement group_id="O2" value="15.4" spread="5.6"/>
                    <measurement group_id="O3" value="18.3" spread="11.9"/>
                    <measurement group_id="O4" value="19.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b</title>
        <description>Mean (SD) change from baseline in biomarker prothrombin time (PT) on Day 28, 1-3 hours post dose.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b</title>
          <description>Mean (SD) change from baseline in biomarker prothrombin time (PT) on Day 28, 1-3 hours post dose.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="5.5"/>
                    <measurement group_id="O2" value="0.4" spread="6.6"/>
                    <measurement group_id="O3" value="2.0" spread="6.6"/>
                    <measurement group_id="O4" value="2.1" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b</title>
        <description>Mean (SD) change from baseline in biomarker International Normalized Ratio (INR) on Day 28, 1-3 hours post dose.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 30mg qd</title>
            <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30mg Bid</title>
            <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 60mg qd</title>
            <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60mg Bid</title>
            <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b</title>
          <description>Mean (SD) change from baseline in biomarker International Normalized Ratio (INR) on Day 28, 1-3 hours post dose.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread=".51"/>
                    <measurement group_id="O2" value="0.03" spread=".62"/>
                    <measurement group_id="O3" value="0.17" spread=".61"/>
                    <measurement group_id="O4" value="0.26" spread=".61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DU-176b 30mg qd</title>
          <description>DU-176b 30mg tablet once daily (qd)
Edoxaban (DU-176b): 30mg tablet once daily</description>
        </group>
        <group group_id="E2">
          <title>DU-176b 30mg Bid</title>
          <description>DU-176b 30mg twice daily (bid)
Edoxaban (DU-176b): 30mg tablet twice daily</description>
        </group>
        <group group_id="E3">
          <title>DU-176b 60mg qd</title>
          <description>DU-176b 60mg once daily (qd)
Edoxaban (DU-176b): 60mg tablet once daily</description>
        </group>
        <group group_id="E4">
          <title>DU-176b 60mg Bid</title>
          <description>DU-176b 60mg tablet two times a day
Edoxaban (DU-176b): 60mg tablet two times a day</description>
        </group>
        <group group_id="E5">
          <title>Warfarin Tablets</title>
          <description>warfarin tablets
warfarin: warfarin tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="180"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>cardiovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>myocardial fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>deafness neurosensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>gastroduodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>intestinal angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>gastric neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">cerebral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>diabetic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>heamorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>ischaemic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study siteâ€™s proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Maxwell, Assoc. Director</name_or_title>
      <organization>Daiichi Sankyo Inc.</organization>
      <phone>732-590-5000</phone>
      <email>wmaxwell@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

